Puma Biotechnology Inc

Research Puma Biotechnology Inc (PBYI) on Bullrun: valuation model: 2.4% undervalued, market cap USD 416.87M, P/E 17.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPBYI
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal2.4% undervalued
• Market capUSD 416.87M
• P/E17.2
• Financial periodFY2025
• RevenueUSD 228.37M
• Revenue growth-0.9%
• Net incomeUSD 31.11M
• Free cash flowUSD 41.73M
• Gross margin74.5%

Valuation Snapshot

Bullrun's latest valuation model marks Puma Biotechnology Inc as 2.4% undervalued; latest market cap is USD 416.87M; P/E is 17.2.

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Frequently asked questions

Is Puma Biotechnology Inc overvalued or undervalued?

Bullrun's valuation model currently marks Puma Biotechnology Inc as 2.4% undervalued.

What is Puma Biotechnology Inc's market cap?

Puma Biotechnology Inc's market capitalization is USD 416.87M.

What is Puma Biotechnology Inc's P/E ratio?

Puma Biotechnology Inc's price-to-earnings (P/E) ratio is 17.2.

What does Puma Biotechnology Inc do?

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.